Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
NCT00790335 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 692
Last updated 2018-03-29
Summary
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.
Conditions
- Deep Vein Thrombosis
- Venous Thrombosis
- Postphlebitic Syndrome
- Venous Thromboembolism
- Post Thrombotic Syndrome
Interventions
- DRUG
-
Recombinant tissue plasminogen activator (rt-PA)
Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
Sponsors & Collaborators
- collaborator OTHER
-
Ontario Clinical Oncology Group (OCOG)
collaborator OTHER -
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
BSN Medical Inc
collaborator INDUSTRY -
Genentech, Inc.
collaborator INDUSTRY -
Medtronic - MITG
collaborator INDUSTRY -
Boston Scientific Corporation
collaborator INDUSTRY -
Mid America Heart Institute
collaborator OTHER -
Society of Interventional Radiology Foundation
collaborator OTHER -
Massachusetts General Hospital
collaborator OTHER -
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Suresh Vedantham, M.D. · Clinical Coordinating Center at Washington University School of Medicine
-
Clive Kearon, MB, MRCP, FRCP(C), PhD · Data Coordinating Center at McMaster University-Ontario Clinical Oncology Group
-
Samuel Z Goldhaber, M.D. · Brigham and Women's Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2017-01-31
- Completion
- 2017-01-31
Countries
- United States
Study Locations
More Related Trials
-
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
NCT03404635 ·Status: COMPLETED
-
AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System
NCT04494035 ·Status: TERMINATED ·Phase: NA
-
PREVENtion of HeartMate II Pump Thrombosis
NCT02158403 ·Status: COMPLETED ·Phase: NA
-
Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis
NCT04411316 ·Status: WITHDRAWN ·Phase: PHASE4
-
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy
NCT06904911 ·Status: RECRUITING ·Phase: PHASE2
-
Statin Use in Patients With Acute VTE
NCT02331095 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
NCT00457002 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment for Blood Clots in the Veins of the Legs
NCT00001713 ·Status: COMPLETED ·Phase: PHASE1
-
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
NCT04248868 ·Status: COMPLETED ·Phase: PHASE3
-
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
NCT00056550 ·Status: COMPLETED ·Phase: PHASE3
-
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569 ·Status: RECRUITING ·Phase: PHASE3
-
Catheter Directed Interventions in Pulmonary Embolism
NCT03595085 ·Status: UNKNOWN ·Phase: NA
-
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
NCT03792152 ·Status: UNKNOWN ·Phase: NA
-
Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis
NCT04670432 ·Status: COMPLETED ·Phase: PHASE3
-
Anti-thrombotic Monotherapy With the HeartMate 3 LVAS
NCT03704220 ·Status: UNKNOWN ·Phase: NA
-
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
NCT01428531 ·Status: COMPLETED
-
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
NCT03988842 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
NCT00521885 ·Status: TERMINATED ·Phase: NA
-
Second Line Endovascular Treatment in Acute DVT
NCT06486181 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
NCT04502017 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
NCT00443053 ·Status: COMPLETED ·Phase: PHASE3
-
Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself
NCT00679705 ·Status: COMPLETED ·Phase: PHASE1
-
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
NCT02979561 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
NCT00291330 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
NCT00252005 ·Status: COMPLETED ·Phase: PHASE2